{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:19:22Z","timestamp":1788391162492,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R35HG011316"],"award-info":[{"award-number":["R35HG011316"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1R01GM141627"],"award-info":[{"award-number":["1R01GM141627"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R35DE030054"],"award-info":[{"award-number":["R35DE030054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R35GM155437"],"award-info":[{"award-number":["R35GM155437"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76374-x","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:05:04Z","timestamp":1785992704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surfaceome CRISPR activation screening uncovers ligands regulating tumor sensitivity to NK cell killing"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-2897","authenticated-orcid":false,"given":"Ravi K.","family":"Dinesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-2887","authenticated-orcid":false,"given":"Imran A.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pari","family":"Gunasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Stiklioraitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-1793","authenticated-orcid":false,"given":"Jeremy R.","family":"Villafuerte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0801-2183","authenticated-orcid":false,"given":"Anirudh","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3968-4908","authenticated-orcid":false,"given":"Rogelio A.","family":"Hernandez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-4196","authenticated-orcid":false,"given":"John B.","family":"Sunwoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4725-8714","authenticated-orcid":false,"given":"Le","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"76374_CR1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","volume":"16","author":"S Sivori","year":"2019","unstructured":"Sivori, S. et al. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol. Immunol. 16, 430\u2013441 (2019).","journal-title":"Cell Mol. Immunol."},{"key":"76374_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"76374_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P. & G\u00f6genur, I. Cytotoxic CD8+\u2009T cells in cancer and cancer immunotherapy. Br. J. Cancer 124, 359\u2013367 (2021).","journal-title":"Br. J. Cancer"},{"key":"76374_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 1\u201311 (2021).","journal-title":"Blood Cancer J."},{"key":"76374_CR5","doi-asserted-by":"publisher","first-page":"e28147","DOI":"10.4161\/onci.28147","volume":"3","author":"H Klingemann","year":"2014","unstructured":"Klingemann, H. Are natural killer cells superior CAR drivers? Oncoimmunology 3, e28147 (2014).","journal-title":"Oncoimmunology"},{"key":"76374_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"76374_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19\u2009+\u2009B cell tumors: a phase 1\/2 trial. Nat. Med 30, 772\u2013784 (2024).","journal-title":"Nat. Med"},{"key":"76374_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","volume":"25","author":"H Klingemann","year":"2023","unstructured":"Klingemann, H. The NK-92 cell line\u201430 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy 25, 451\u2013457 (2023).","journal-title":"Cytotherapy"},{"key":"76374_CR9","doi-asserted-by":"crossref","unstructured":"Park, H., Kim, G., Kim, N., Ha, S. & Yim, H. Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Front. Immunol. 15, 1454427 (2024).","DOI":"10.3389\/fimmu.2024.1454427"},{"key":"76374_CR10","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41588-021-00889-w","volume":"53","author":"M Sheffer","year":"2021","unstructured":"Sheffer, M. et al. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nat. Genet. 53, 1196\u20131206 (2021).","journal-title":"Nat. Genet."},{"key":"76374_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29469-0","volume":"13","author":"D Bernareggi","year":"2022","unstructured":"Bernareggi, D. et al. CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity. Nat. Commun. 13, 1899 (2022).","journal-title":"Nat. Commun."},{"key":"76374_CR12","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood.2022015646","volume":"140","author":"M Chiba","year":"2022","unstructured":"Chiba, M. et al. Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. Blood 140, 1951\u20131963 (2022).","journal-title":"Blood"},{"key":"76374_CR13","doi-asserted-by":"publisher","first-page":"e010699","DOI":"10.1136\/jitc-2024-010699","volume":"13","author":"S Guia","year":"2025","unstructured":"Guia, S. et al. Genome-wide CRISPR\/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing. J. Immunother. Cancer 13, e010699 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"76374_CR14","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.3389\/fimmu.2019.02879","volume":"10","author":"X Zhuang","year":"2019","unstructured":"Zhuang, X., Veltri, D. P. & Long, E. O. Genome-wide CRISPR screen reveals cancer cell resistance to NK cells induced by NK-derived IFN-\u03b3. Front. Immunol. 10, 2879 (2019).","journal-title":"Front. Immunol."},{"key":"76374_CR15","doi-asserted-by":"publisher","first-page":"e47362","DOI":"10.7554\/eLife.47362","volume":"8","author":"MF Pech","year":"2019","unstructured":"Pech, M. F. et al. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. eLife 8, e47362 (2019).","journal-title":"eLife"},{"key":"76374_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02513-w","volume":"22","author":"H Mei","year":"2021","unstructured":"Mei, H. et al. Surfaceome CRISPR screen identifies OLFML3 as a rhinovirus-inducible IFN antagonist. Genome Biol. 22, 297 (2021).","journal-title":"Genome Biol."},{"key":"76374_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald, T., Krummel, M. F., Smyth, M. J. & Barry, K. C. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat. Immunol. 21, 835\u2013847 (2020).","journal-title":"Nat. Immunol."},{"key":"76374_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nature14136","volume":"517","author":"S Konermann","year":"2015","unstructured":"Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583\u2013588 (2015).","journal-title":"Nature"},{"key":"76374_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07901-8","volume":"9","author":"KR Sanson","year":"2018","unstructured":"Sanson, K. R. et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat. Commun. 9, 5416 (2018).","journal-title":"Nat. Commun."},{"key":"76374_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nmeth.3871","volume":"13","author":"A Chavez","year":"2016","unstructured":"Chavez, A. et al. Comparison of Cas9 activators in multiple species. Nat. Methods 13, 563\u2013567 (2016).","journal-title":"Nat. Methods"},{"key":"76374_CR21","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s43018-021-00282-w","volume":"2","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat. Cancer 2, 1406\u20131422 (2021).","journal-title":"Nat. Cancer"},{"key":"76374_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri2154","volume":"7","author":"ND Huntington","year":"2007","unstructured":"Huntington, N. D., Vosshenrich, C. A. J. & Di Santo, J. P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703\u2013714 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"76374_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1084\/jem.20102548","volume":"208","author":"Y Li","year":"2011","unstructured":"Li, Y., Wang, Q. & Mariuzza, R. A. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J. Exp. Med. 208, 703\u2013714 (2011).","journal-title":"J. Exp. Med."},{"key":"76374_CR24","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1084\/jem.20090681","volume":"206","author":"CS Brandt","year":"2009","unstructured":"Brandt, C. S. et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495\u20131503 (2009).","journal-title":"J. Exp. Med."},{"key":"76374_CR25","doi-asserted-by":"publisher","first-page":"e2015024118","DOI":"10.1073\/pnas.2015024118","volume":"118","author":"S Wisnovsky","year":"2021","unstructured":"Wisnovsky, S. et al. Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7. Proc. Natl. Acad. Sci. 118, e2015024118 (2021).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"76374_CR26","doi-asserted-by":"publisher","first-page":"100477","DOI":"10.1016\/j.jbc.2021.100477","volume":"296","author":"A Yoshimura","year":"2021","unstructured":"Yoshimura, A. et al. Identification and functional characterization of a Siglec-7 counter-receptor on K562 cells. J. Biol. Chem. 296, 100477 (2021).","journal-title":"J. Biol. Chem."},{"key":"76374_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/sita.200700140","volume":"7","author":"G Pedraza-Alva","year":"2007","unstructured":"Pedraza-Alva, G. & Rosenstein, Y. CD43 \u2013 One molecule, many tales to recount. Signal Transduct. 7, 372\u2013385 (2007).","journal-title":"Signal Transduct."},{"key":"76374_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.tripleo.2005.08.038","volume":"102","author":"VL Woo","year":"2006","unstructured":"Woo, V. L., Bhuiya, T. & Kelsch, R. Assessment of CD43 expression in adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, and monomorphic adenomas. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endodontology 102, 495\u2013500 (2006).","journal-title":"Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endodontology"},{"key":"76374_CR29","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1006\/bbrc.1997.7334","volume":"238","author":"R Sikut","year":"1997","unstructured":"Sikut, R., Nilsson, O., Baeckstr\u00f6m, D. & Hansson, G. C. Colon adenoma and cancer cells aberrantly express the leukocyte-associated sialoglycoprotein CD43. Biochem. Biophys. Res. Commun. 238, 612\u2013616 (1997).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"76374_CR30","doi-asserted-by":"publisher","first-page":"e22476","DOI":"10.1096\/fj.202200045R","volume":"36","author":"K-E Aryee","year":"2022","unstructured":"Aryee, K.-E. et al. Enhanced development of functional human NK cells in NOD-scid-IL2rgnull mice expressing human IL15. FASEB J. 36, e22476 (2022).","journal-title":"FASEB J."},{"key":"76374_CR31","doi-asserted-by":"crossref","unstructured":"Senbanjo, L. T. & Chellaiah, M. A. CD44: A multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front. Cell Dev. Biol. 5, 18 (2017).","DOI":"10.3389\/fcell.2017.00018"},{"key":"76374_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez, C. X. et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 10, 232\u2013253 (2020).","journal-title":"Cancer Discov."},{"key":"76374_CR33","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/2326-6066.CIR-18-0098","volume":"6","author":"V Cremasco","year":"2018","unstructured":"Cremasco, V. et al. FAP delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors. Cancer Immunol. Res. 6, 1472\u20131485 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"76374_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","volume":"611","author":"AT Krishnamurty","year":"2022","unstructured":"Krishnamurty, A. T. et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature 611, 148\u2013154 (2022).","journal-title":"Nature"},{"key":"76374_CR35","doi-asserted-by":"publisher","first-page":"101887","DOI":"10.1016\/j.smim.2024.101887","volume":"73","author":"EN Kukan","year":"2024","unstructured":"Kukan, E. N., Fabiano, G. L. & Cobb, B. A. Siglecs as modulators of macrophage phenotype and function. Semin. Immunol. 73, 101887 (2024).","journal-title":"Semin. Immunol."},{"key":"76374_CR36","doi-asserted-by":"crossref","unstructured":"Herzog, S., Fragkou, P. C., Arneth, B. M., Mkhlof, S. & Skevaki, C. Myeloid CD169\/Siglec1: An immunoregulatory biomarker in viral disease. Front. Med. 9, 979373 (2022).","DOI":"10.3389\/fmed.2022.979373"},{"key":"76374_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41590-022-01394-w","volume":"24","author":"S-C Oh","year":"2023","unstructured":"Oh, S.-C. et al. NgR1 is an NK cell inhibitory receptor that destabilizes the immunological synapse. Nat. Immunol. 24, 463\u2013473 (2023).","journal-title":"Nat. Immunol."},{"key":"76374_CR38","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"76374_CR39","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s12026-017-8942-y","volume":"65","author":"P Rosenstock","year":"2017","unstructured":"Rosenstock, P., Horstkorte, R., Gnanapragassam, V. S., Harth, J. & Kielstein, H. Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans. Immunol. Res. 65, 1017\u20131024 (2017).","journal-title":"Immunol. Res."},{"key":"76374_CR40","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1021\/acscentsci.1c00064","volume":"7","author":"S Hong","year":"2021","unstructured":"Hong, S. et al. Modulation of siglec-7 signaling via in situ-created high-affinity cis-ligands. ACS Cent. Sci. 7, 1338\u20131346 (2021).","journal-title":"ACS Cent. Sci."},{"key":"76374_CR41","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1091\/mbc.e10-07-0586","volume":"22","author":"JL Cannon","year":"2011","unstructured":"Cannon, J. L. et al. CD43 interaction with ezrin-radixin-moesin (ERM) proteins regulates T-cell trafficking and CD43 phosphorylation. Mol. Biol. Cell 22, 954\u2013963 (2011).","journal-title":"Mol. Biol. Cell"},{"key":"76374_CR42","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1084\/jem.20021602","volume":"199","author":"J Tong","year":"2004","unstructured":"Tong, J. et al. CD43 regulation of T cell activation is not through steric inhibition of T cell\u2013APC interactions but through an intracellular mechanism. J. Exp. Med. 199, 1277\u20131283 (2004).","journal-title":"J. Exp. Med."},{"key":"76374_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-cancerbio-061521-082320","volume":"7","author":"MJ Raftery","year":"2023","unstructured":"Raftery, M. J., Franz\u00e9n, A. S. & Pecher, G. CAR NK cells: the future is now. Annu. Rev. Cancer Biol. 7, 229\u2013246 (2023).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"76374_CR44","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-022-04494-7","volume":"603","author":"M Legut","year":"2022","unstructured":"Legut, M. et al. A genome-scale screen for synthetic drivers of T cell proliferation. Nature 603, 728\u2013735 (2022).","journal-title":"Nature"},{"key":"76374_CR45","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1038\/s41588-023-01554-0","volume":"55","author":"SR McCutcheon","year":"2023","unstructured":"McCutcheon, S. R. et al. Transcriptional and epigenetic regulators of human CD8+\u2009T cell function identified through orthogonal CRISPR screens. Nat. Genet 55, 2211\u20132223 (2023).","journal-title":"Nat. Genet"},{"key":"76374_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","volume":"609","author":"J Carnevale","year":"2022","unstructured":"Carnevale, J. et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609, 174\u2013182 (2022).","journal-title":"Nature"},{"key":"76374_CR47","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1016\/j.cell.2023.08.013","volume":"186","author":"F Blaeschke","year":"2023","unstructured":"Blaeschke, F. et al. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell 186, 4216\u20134234.e33 (2023).","journal-title":"Cell"},{"key":"76374_CR48","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"76374_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan, A. E. et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature 629, 211\u2013218 (2024).","journal-title":"Nature"},{"key":"76374_CR50","doi-asserted-by":"publisher","first-page":"eabn5647","DOI":"10.1126\/science.abn5647","volume":"378","author":"KA Freitas","year":"2022","unstructured":"Freitas, K. A. et al. Enhanced T cell effector activity by targeting the Mediator kinase module. Science 378, eabn5647 (2022).","journal-title":"Science"},{"key":"76374_CR51","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.cell.2024.01.035","volume":"187","author":"V Tieu","year":"2024","unstructured":"Tieu, V. et al. A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell 187, 1278\u20131295.e20 (2024).","journal-title":"Cell"},{"key":"76374_CR52","doi-asserted-by":"crossref","unstructured":"Zhuang, X. et al. Functional genomics identifies N-acetyllactosamine extension of complex N-glycans as a mechanism to evade lysis by natural killer cells. Cell Rep. 43, 114105 (2024).","DOI":"10.1016\/j.celrep.2024.114105"},{"key":"76374_CR53","doi-asserted-by":"publisher","first-page":"e1013157","DOI":"10.1371\/journal.ppat.1013157","volume":"21","author":"RK Dinesh","year":"2025","unstructured":"Dinesh, R. K. et al. Membrane-wide screening identifies potential tissue-specific determinants of SARS-CoV-2 tropism. PLOS Pathog. 21, e1013157 (2025).","journal-title":"PLOS Pathog."},{"key":"76374_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29205-8","volume":"13","author":"J Joung","year":"2022","unstructured":"Joung, J. et al. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nat. Commun. 13, 1606 (2022).","journal-title":"Nat. Commun."},{"key":"76374_CR55","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-021-03879-4","volume":"597","author":"RA Kamber","year":"2021","unstructured":"Kamber, R. A. et al. Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature 597, 549\u2013554 (2021).","journal-title":"Nature"},{"key":"76374_CR56","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1016\/j.immuni.2023.11.008","volume":"56","author":"O Dufva","year":"2023","unstructured":"Dufva, O. et al. Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers. Immunity 56, 2816\u20132835.e13 (2023).","journal-title":"Immunity"},{"key":"76374_CR57","doi-asserted-by":"publisher","first-page":"919097","DOI":"10.3389\/fcimb.2022.919097","volume":"12","author":"SSF Lende","year":"2022","unstructured":"Lende, S. S. F. et al. CD169 (Siglec-1) as a robust human cell biomarker of toll-like receptor 9 agonist immunotherapy. Front. Cell. Infect. Microbiol. 12, 919097 (2022).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"76374_CR58","doi-asserted-by":"publisher","first-page":"e0166680","DOI":"10.1371\/journal.pone.0166680","volume":"11","author":"T Shiota","year":"2016","unstructured":"Shiota, T. et al. The clinical significance of CD169-positive lymph node macrophage in patients with breast cancer. PLoS ONE 11, e0166680 (2016).","journal-title":"PLoS ONE"},{"key":"76374_CR59","doi-asserted-by":"publisher","first-page":"8042","DOI":"10.4049\/jimmunol.175.12.8042","volume":"175","author":"M Matsumoto","year":"2005","unstructured":"Matsumoto, M. et al. CD43 functions as a ligand for E-selectin on activated T cells1. J. Immunol. 175, 8042\u20138050 (2005).","journal-title":"J. Immunol."},{"key":"76374_CR60","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1182\/blood-2005-05-2112","volume":"107","author":"RC Fuhlbrigge","year":"2006","unstructured":"Fuhlbrigge, R. C., King, S. L., Sackstein, R. & Kupper, T. S. CD43 is a ligand for E-selectin on CLA+ human T cells. Blood 107, 1421\u20131426 (2006).","journal-title":"Blood"},{"key":"76374_CR61","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.4049\/jimmunol.166.6.3637","volume":"166","author":"TK van den Berg","year":"2001","unstructured":"van den Berg, T. K. et al. Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1). J. Immunol. 166, 3637\u20133640 (2001).","journal-title":"J. Immunol."},{"key":"76374_CR62","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/354233a0","volume":"354","author":"Y Rosenstein","year":"1991","unstructured":"Rosenstein, Y. et al. CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature 354, 233\u2013235 (1991).","journal-title":"Nature"},{"key":"76374_CR63","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1182\/blood.V91.12.4632","volume":"91","author":"JM Serrador","year":"1998","unstructured":"Serrador, J. M. et al. CD43 interacts with moesin and ezrin and regulates its redistribution to the uropods of T lymphocytes at the cell-cell contacts. Blood 91, 4632\u20134644 (1998).","journal-title":"Blood"},{"key":"76374_CR64","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1083\/jcb.140.4.885","volume":"140","author":"S Yonemura","year":"1998","unstructured":"Yonemura, S. et al. Ezrin\/radixin\/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J. Cell Biol. 140, 885\u2013895 (1998).","journal-title":"J. Cell Biol."},{"key":"76374_CR65","doi-asserted-by":"publisher","first-page":"840388","DOI":"10.3389\/fimmu.2022.840388","volume":"13","author":"L-Y Chang","year":"2022","unstructured":"Chang, L.-Y. et al. Molecular basis and role of Siglec-7 ligand expression on chronic lymphocytic leukemia B cells. Front. Immunol. 13, 840388 (2022).","journal-title":"Front. Immunol."},{"key":"76374_CR66","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/bloodadvances.2021006805","volume":"6","author":"J Daly","year":"2022","unstructured":"Daly, J. et al. Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell\u2013mediated tumor responses. Blood Adv. 6, 3352\u20133366 (2022).","journal-title":"Blood Adv."},{"key":"76374_CR67","doi-asserted-by":"publisher","first-page":"e2215376120","DOI":"10.1073\/pnas.2215376120","volume":"120","author":"BAH Smith","year":"2023","unstructured":"Smith, B. A. H. et al. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint. Proc. Natl. Acad. Sci. 120, e2215376120 (2023).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"76374_CR68","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/eji.201948357","volume":"50","author":"RK Dinesh","year":"2020","unstructured":"Dinesh, R. K. et al. Transcription factor binding at Ig enhancers is linked to somatic hypermutation targeting. Eur. J. Immunol. 50, 380\u2013395 (2020).","journal-title":"Eur. J. Immunol."},{"key":"76374_CR69","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature10348","volume":"477","author":"JE Carette","year":"2011","unstructured":"Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340\u2013343 (2011).","journal-title":"Nature"},{"key":"76374_CR70","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","volume":"185","author":"L Labanieh","year":"2022","unstructured":"Labanieh, L. et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell 185, 1745\u20131763.e22 (2022).","journal-title":"Cell"},{"key":"76374_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"76374_CR72","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"key":"76374_CR73","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10616-006-9028-1","volume":"51","author":"A Delgado-Ca\u00f1edo","year":"2006","unstructured":"Delgado-Ca\u00f1edo, A., Santos, D. G. D. os, Chies, J. A. B., Kvitko, K. & Nardi, N. B. Optimization of an electroporation protocol using the K562 cell line as a model: role of cell cycle phase and cytoplasmic DNAses. Cytotechnology 51, 141\u2013148 (2006).","journal-title":"Cytotechnology"},{"key":"76374_CR74","doi-asserted-by":"publisher","first-page":"e20201529","DOI":"10.1084\/jem.20201529","volume":"218","author":"R-S Huang","year":"2021","unstructured":"Huang, R.-S., Lai, M.-C., Shih, H.-A. & Lin, S. A robust platform for expansion and genome editing of primary human natural killer cells. J. Exp. Med. 218, e20201529 (2021).","journal-title":"J. Exp. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76374-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:59:43Z","timestamp":1788389983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76374-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76374"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76374-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.B.S has NK cell related funding, which includes NIH grant R35DE030054 and the Tai Tsun Wu Research Fund for Natural Killer Cell Immunotherapy. J.B.S. is a scientific cofounder of Indapta Therapeutics and serves on its scientific advisory board. Pending patents related to NK cells include USPTO no. 17\/766,019, entitled \u201cMethod for differentiating innate lymphoid cells for immunotherapy,\u201d and USPTO no. 64\/034,506, entitled \u201cFeeder-cell free system to differentiate tissue-resident NK cells for adoptive cell therapy\u201d. L.C. is a member of the scientific advisory board of Arbor Biotechnologies. L.C. has equity interests in Auto Bio, Phylo, and Acrobat Genomics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9442"}}